A 2014 study further elaborated on the AR–JUND interaction and concluded that its inhibition by pharmaceuticals like GWARJD10 can reverse the expression of SSAT and thus limit the carcinogenic impact of aberrant ROS production, thus elucidating a novel tumor preventive target [145] (Figure 3). The gene discussed is AR; the disease is neoplasm.